ConforMIS
323 Vintage Park Drive
Suite C
Foster City
California
94404
United States
Tel: 650-286-4151
Fax: 650-286-4160
Website: http://www.conformis.com/
172 articles about ConforMIS
-
Conformis, Inc. Announces Proposed Public Offering of Common Stock - Feb 11, 2021
2/11/2021
Conformis, Inc. announced that it intends to offer shares of its common stock in an underwritten public offering.
-
Conformis, Inc. and SITES Medical Announce Development & Supply Agreement
1/21/2021
Conformis, Inc. (NASDAQ:CFMS) and SITES Medical, a firm dedicated to inventing and de-risking new orthopedic medical device technologies, today announced they have entered into a non-exclusive development and supply agreement. The companies will work together to incorporate SITES Medical’s proprietary OsteoSync Ti Technology into future Conformis’ cementless total knee replacement products. “We are excited to be part
-
Conformis Announces U.S. Commercial Launch of Cordera™ Match Hip SystemCordera™ Match Hip System combines the proven Cordera™ hip stem with Conformis’ state-of-the-art, personalized pre-operative plans and patient-specific instruments.
12/17/2020
Conformis, Inc. announced the U.S. commercial launch of the Company’s new Cordera™ Match Hip System. The Company previously announced 510 clearance by the U.S. Food and Drug Administration for the Cordera™ Hip System on September 29, 2020, and Cordera™ Match represents one of multiple planned product extensions featuring the proven Cordera™ Hip System.
-
Conformis Announces Bart Lagae as VP, International Sales & Marketing; Inducement Grant Reported
11/9/2020
Conformis, Inc. announced that the Company has appointed Bart Lagae as its new VP, International Sales & Marketing.
-
Conformis, Inc. to Participate in the 2020 Oppenheimer Fall MedTech Summit
10/28/2020
Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Officer, will participate in the virtual 2020 Oppenheimer Fall MedTech Summit taking place Thursday, November 12, 2020, in one-on-one meetings. About Conformis, Inc. Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and
-
Conformis Reports Preliminary Third Quarter Revenue ResultsEarnings Call to be Hosted on November 4, 2020
10/6/2020
Conformis, Inc. (NASDAQ:CFMS) today announced preliminary, unaudited, revenue results for the third quarter ended September 30, 2020. Expected Q 3 Summary: Total revenue of approximately $16.1 million, down 7% year-over-year on a reported and constant currency basis Royalty revenue of $0.1 million Product revenue of approximately $16.0 million, down 7% year-over-year on a reported and constant currency basis - U.S. product revenu
-
Conformis Announces 510(k) Clearance for Cordera™ Hip SystemCordera™ Hip System
9/29/2020
Conformis, Inc. (NASDAQ: CFMS) today announced 510(k) clearance by the U.S. Food and Drug Administration of the Company’s new Cordera™ Hip System. The first product in the Conformis hip product line, the Conformis Hip System, was launched commercially in November 2019 and provided a patient-specific stem. The Cordera™ Hip System is an uncemented, primary total hip replacement composed of femoral (thigh) and acetabular (socket of the hip bo
-
Conformis, Inc. Announces $17.25 Million Registered Direct Offering Priced At-The-Market
9/24/2020
Conformis, Inc. announced it has entered into a definitive agreement with a healthcare focused institutional investor to sell to the investor, in a registered direct offering priced at-the-market under Nasdaq rules
-
Conformis, Inc. to Present at the 2020 Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
9/16/2020
Conformis, Inc. (NASDAQ:CFMS) will participate in the 2020 Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held September 21-23, 2020 in a virtual format. Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Officer, will represent the Company in a session scheduled to begin at 2:30 pm ET on Tuesday, September 22, 2020. The live webcast of the presentation will be available by visiting
-
Conformis, Inc. to Present at the 2020 H.C. Wainwright Global Investment Conference
9/8/2020
Conformis, Inc. (NASDAQ:CFMS) will participate in the upcoming 2020 H.C. Wainwright 22nd Annual Global Investment Conference, to be held virtually on September 14-16, 2020.
-
Conformis, Inc. to Participate in the 2020 Wells Fargo Virtual Healthcare Conference
9/2/2020
Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and members of the Company’s executive management team will participate in the 2020 Wells Fargo Virtual Healthcare Conference taking place September 9-10, 2020, in one-on-one meetings. About Conformis, Inc. Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufac
-
Conformis Announces Achievement of Second Milestone Under Development and License Agreements
8/20/2020
Conformis, Inc. (NASDAQ:CFMS) announced today that it completed the second of three milestones pursuant to the License Agreement and Development Agreement with Howmedica Osteonics Corp., a wholly owned subsidiary of Stryker Corporation also known as Stryker Orthopaedics, under which Conformis is developing patient-specific instrumentation (“PSI”) for use in connection with Stryker’s knee implant offerings. The Company will receive an addition
-
Conformis Announces Farzin Khaghani as VP, US Marketing; Inducement Grants Reported
8/13/2020
Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed Farzin Khaghani as its new VP, US Marketing.
-
90% Patient Satisfaction Reported in Peer-Reviewed Clinical Study of Conformis iTotal PS Knee Replacements
8/10/2020
Clinical research published online in July 2020 in The Journal of Bone and Joint Surgery Reviews found that the patients studied, who all received Conformis patient-specific iTotal PS (posterior-stabilized) knee replacement implants, were 90% satisfied, or very satisfied, 18–28 months post-surgery.
-
Conformis Reports Second Quarter 2020 Financial Results and Announces Planned Portfolio Expansion Targeted at Ambulatory Surgical Centers
8/5/2020
Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the second quarter ended June 30, 2020.
-
Conformis, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
7/23/2020
Conformis, Inc. (NASDAQ:CFMS) announced today that management will present at the Canaccord Genuity 40th Annual Growth Conference. The event is being held virtually and will take place between August 11 and 13, 2020. For more information, please visit https://www.canaccordgenuity.com/capital-markets/about-us/events . Webcasted Presentation Event: Canaccord Genuity 40th Annual Growth Conference Date: Wednesday, August 12,
-
Conformis Reports Preliminary Second Quarter Revenue Results, Amendment to Credit Agreement
7/6/2020
Earnings Call to be Hosted on August 5, 2020 BILLERICA, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants designed to fit each patient’s unique anatomy, today announced preliminary, unaudited, revenue results for the second quarter ended June 30, 2020. Expected Q2 Summary: Total revenue of approximately $19.5
-
Conformis Announces 510(k) Clearance for iTotal® Identity PSiTotal® Identity PS joins iTotal® Identity CR as the latest personalized knee technology from Conformis
6/22/2020
Conformis, Inc. (NASDAQ:CFMS) today announced 510(k) clearance by the U.S. Food and Drug Administration of the Company’s next generation iTotal ® Identity PS Knee System. The iTotal ® Identity PS Knee System uses proprietary advanced imaging and design software, to deliver a patient-specific, pre-operative surgical plan with a comprehensive set of iJig instruments and patient-matched implants. Updates to this system include stem extensio
-
Conformis Announces Settlement of Patent Dispute
5/28/2020
Conformis and Zimmer Biomet settled disputes related to Patient-Specific Instrument Patents for Use with Off-the-Shelf Knee, Hip, and Shoulder Implants
-
Prestigious Klee Family Foundation Prize 2020 Awarded for Outstanding Scientific Work Identifying Patient-Specific Approach as Better Way to Optimize Knee Implant Design
5/21/2020
Dr. Malte Asseln awarded annual prize by German Society for Biomedical Engineering at the VDE Association and the Klee Family Foundation for his scientific computer-and-image-based workflow to optimize knee implant design